Perrigo Company plc (NYSE: PRGO; TASE) today announced that Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Ltd. and Opiant Pharmaceuticals initiated patent litigation on October 25, 2018 in the United States District Court for the District of New Jersey regarding Perrigo’s Paragraph IV Abbreviated New Drug Application for naloxone hydrochloride nasal spray 4mg,
October 26, 2018
· 5 min read